Pfizer Gets Okay for New Drug (PFE)
Pfizer Inc. (NYSE: PFE) has received approval from the US Food and Drug Administration to sell its kidney cancer drug, Inlyta, in the US. The drug is expected to generate about $140 million in revenues this year, and as much…
Pfizer Inc. (NYSE: PFE) has received approval from the US Food and Drug Administration to sell its kidney cancer drug, Inlyta, in the US. The drug is expected to generate about $140 million in revenues this year, and as much as $800 million annually by 2017.
Shares have not reacted, down about -0.7% currently, because the drug is the latest of seven treatments for kidney cancer.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
